Anti-AIDS drug by Ranbaxy

- †*15. SHRI JAYANTILAL BAROT: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:
- (a) the details of the drugs manufactured in India recognised by the World Health Organisation;
- (b) whether it is a fact that the World Health Organisation has recognised anti-AIDS drug manufactured by Ranbaxy;'
- (c) if so, by which name it has been recognised and at which number the World Health Organisation has listed it as an anti-AIDS drug;
- (d) whether any recognised company other than Ranbaxy has manufactured anti-AIDS drug; and
- (e) if so, whether that company has also applied for recognition from the World Health Organisation?

THE MINISTER OF HEALTH AND FAMILY WELFARE (SHRIMATI SUSHMA SWARAJ): (a) to (e) The World Health Organisation has recognised three anti-AIDS drugs manufactured by two leading Indian pharmaceutical companies namely Cipla and Ranbaxy, for supply to UN agencies. These durgs are (i) Lamivudine, (ii) Zidovudine, and (iii) Nevirapine.

Detalis of the drugs manufactured in India and recognised by the World Health Organisation are in the Statement (with their reference numbers) (See *below*). The anti-AIDS drugs, which are manufactured by Ranbaxy and recognised by the World Health Organisation are: (i) Lamivudine; (ii) Lamivudine plus Zidovudine combination, (iii) Nevirapine and (iv) Zidovudine.

Other than Ranbaxy, the World Health Organisation recognises Cipla, manufacture of anti-AIDS drugs: (a) Lamivudine, (b) Lamivudine plus Zidovudine combination, (c) Nevirapine, (d) Zidovudine-tablets and solution.

[†]Original notice of the question was received in Hindi.

Statement

Indian suppliers whose HIV-related medicines have been found acceptable in principle for procurement by UN agencies (updated 4th July 2003)

| Ref. No. | International Non- proprietary Name | Strength (INN) | Dosage form | Supplier | Manufacturing site |
|-------------|--|----------------|----------------|------------|--------------------|
| 032 | Lamivudine | 150mg | Tablet | Ranbaxy | Dewas |
| 043 | Lamivudine | 150mg | Tablet | Cipla | Kurkumbh |
| 053 | Lamivudine | 50mg/5ml | Solution | Cipla Ltd. | Vikhroli |
| 033 | Lamivudine+ Zidovudine | 150/300 mg | Tablet | Ranbaxy | Dewa |
| 060 | Lamivudine+ Zidovudine | 150/300mg | Tablet | Cipla Ltd. | Vikhroli |
| 031 | Nevirapine | 200mg | Tablet | Ranbaxy | Dewas |
| 039 | Nevirapine | 200mg | Tablet | Cipla Ltd. | Vikhroli |
| 030 | Zidovudine | 300mg | Tablet | Ranbaxy | Dewas |
| 051 | Zidovudine | 300mg | Tablet | Cipla | Vikhroli |
| 052 | Zidovudine | 100mg | Caps. | Cipla | Vikhroli |
| 054 | Zidovudine | 50mg/5ml | Solution | Cipla Ltd. | Vikhroli |

Circulation and sale of newspapers

- *16. SHRIMATI N.P. DURGA: Will the Minister of INFORMATION AND BROADCASTING be pleased to state:
- (a) whether circulation and sale of newspapers are up in the country during the last three years;
 - (b) if so, the details thereof; and
 - (c) the share of advertising revenue?

THE MINISTER OF STATE OF THE MINISTRY OF INFORMATION AND BROADCASTING (SHRI RAVI SHANKAR PRASAD): (a) to (c) As per Annual Statements filed by newspapers with RNI, the circulation and sale of newspapers show decline during the last three years, as per information given below: